App-Quantinova.ai

Low incidence of thromboembolism in hospitalized COVID-19 patients despite a very low thromboprophylaxis rate in Thailand

N. Tangcheewinsirikul - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Low molecular weight heparin beyond 12 months in patients with cancer associated thrombosis. CAT-LONG study.

S. Lopez-Ruz - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Heparin

Lung Ultrasound (LUS) for Thrombosis in COVID-19 Patients

K. Bielosludtseva - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Lupus anticoagulant as predictor for thrombosis in critically ill COVID-19 patients: a retrospective cohort study

T. Noordermeer - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Major gastrointestinal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: a score to identify high risk patients

J. CATELLA - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Management of Patients with Unprovoked Venous Thromboembolism and a Low Risk of Recurrence with the Vienna Prediction Model: A Prospective Cohort Study

S. Eichinger - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Matrix metalloproteinase-13: a novel player of platelet activation and in vivo thrombus formation

S. Momi - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Matrix metalloproteinases are associated with poor prognosis in hospitalized patients with COVID-19

M. Marcos-Jubilar - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Measuring Factor VII Activating Protease (FSAP) in venous thrombosis using a newly developed FSAP generation assay

M. Etscheid - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Mechanisms of cancer associated thrombosis in gynaecological cancer patients-tumour or treatment effect?

M. Ward - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Thrombomodulin alfa

Microparticles and D-Dimers improve prediction of chemotherapy- associated thrombosis in cancer patients

M. CHEKKAL - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Mitochondrial ATP generation in stimulated platelets is essential for granule secretion but dispensable for aggregation and procoagulant activity

P. Kulkarni - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Evithrom

Monitoring the persistence of vaccine-induced immune thrombotic thrombocytopenia (VITT) antibodies and their pathogenicity

C. Lee - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Mortality associated with venous thrombosis in Brazil: evidence of inequalities between low/middle- and high-income countries

I. Batista - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

N-Acetyl Cysteine Prevents Occlusive Arterial Thrombosis in a Dose-Dependent Manner

C. Bresette - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N-acetylcysteine

Na+/K+ ATPase alpha 1 subunit participates in platelet signaling and is a potential anti-thrombotic target

O. Li - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

L-Tyrosine

Neutrophils and platelets collaborate to induce an increase NET formation during JAK2V617F positive myeloproliferative neoplasms

A. Guy - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Non-O Blood Type is Risk Factor for Venous Thromboembolism in Acutely Injured Patients Requiring Orthopaedic Surgery

P. Schneider - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Heparin

Outcomes in clinical studies of interventions for venous thromboembolism in non-pregnant adults: A scoping review

T. Tritschler - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Overall Haemostatic Potential (OHP) assay can risk stratify for venous thromboembolism recurrence in anticoagulated patients

J. Wang - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Filters

7277 Abstracts